DASATINIB VIATRIS 50 mg, comprimé pelliculé, DASATINIB VIATRIS 70 mg, comprimé pelliculé
IPC 2022-067
Phase 2 small_molecule active
Quick answer
DASATINIB VIATRIS 50 mg, comprimé pelliculé, DASATINIB VIATRIS 70 mg, comprimé pelliculé for acute myeloid leukemia is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- acute myeloid leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active